心脏磁共振评估转甲状腺素蛋白淀粉样心肌病的自然病程与治疗反应
本研究利用心脏磁共振细胞外容积(ECV)标测追踪转甲状腺素蛋白淀粉样心肌病(ATTR-CM)患者淀粉样负荷随时间的变化。未治疗患者1年时36%进展、2年时62%进展,平均ECV分别增加4.1%和6.8%;接受patisiran治疗者1年88%、2年100%保持ECV稳定。
要点
- ECV标测可无创追踪ATTR-CM患者心脏淀粉样负荷的动态变化。
- 未治疗患者ECV进展比例随时间显著增加,1年36%、2年62%。
- 1年ECV进展是死亡的独立预测因子,HR 2.021。
核心结论
- 心脏磁共振ECV标测可追踪ATTR-CM患者心脏淀粉样负荷变化及治疗反应。
- ECV变化与患者结局独立相关。
研究设计与样本
- 共纳入189例ATTR-CM患者,其中未治疗组119例、patisiran组70例。
- 基线、1年及2年随访时行CMR检查,1年随访160例、2年随访75例。
- CMR反应按ECV变化分级:进展(增加≥5%)、稳定(变化<5%)、消退(降低≥5%)。
主要发现
- 未治疗患者中,1年时36%进展,2年时进展比例显著增至62%。
- 未治疗患者平均ECV在1年后增加4.1%、2年后增加6.8%,并伴随生物标志物和结构参数显著恶化。
- patisiran治疗组在两个时间点平均ECV均无显著差异,1年88%、2年100%患者ECV保持稳定,结构参数亦保持稳定。
临床怎么用
- 可将CMR ECV标测用于ATTR-CM患者淀粉样负荷的纵向监测和疗效评估。
- ECV进展可辅助识别死亡风险较高的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Cardiovascular magnetic resonance (CMR) and extracellular volume (ECV) mapping can measure amyloid burden in vivo. This study sought to assess the natural history of transthyretin amyloid cardiomyopathy (ATTR-CM) in terms of amyloid deposition burden (ECV) over time, changes in cardiac amyloid load following treatment with patisiran, and the association between change in ECV and mortality. METHODS: All 189 patients (untreated = 119, patisiran = 70) underwent assessment with CMR at baseline, 160 patients (untreated = 94, patisiran = 66) had a 1-year follow-up CMR and 75 patients (untreated = 42, patisiran = 33) had a 2-year follow-up CMR, of whom 36 patients (untreated = 17, patisiran = 29) had follow-up CMR at both timepoints. CMR response was graded by change in ECV: progression (≥5% increase), stable (<5% change) and regression (≥5% decrease). RESULTS: In untreated patients, 36% progressed at 1 year which significantly increased to 62% at 2 years. Mean increase in ECV of 4.1% (after 1 year) and 6.8% (after 2 years) was observed and associated with significant worsening in biomarkers and structural parameters. No significant difference in mean ECV was observed following treatment with patisiran at both timepoints. Stable ECV was observed in 88% of patients (after 1 year) and 100% of patients (after 2 years). Structural parameters remained stable following treatment. ECV progression after 1 year was independently associated with mortality after adjusting for known predictors (hazard ratio 2.021; 95% confidence interval 1.081-3.781; P = .028). CONCLUSIONS: CMR with ECV mapping can track changes in cardiac amyloid burden and treatment response in ATTR-CM, with changes in ECV being independently associated with outcomes.
引用
- Patel RK, Ioannou A, Sheikh A, et al. Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance. Eur Heart J. 2025. PMID: 40643267. doi:10.1093/eurheartj/ehaf412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。